{"product_id":"biolegend-324202","title":"Biolegend, 324202, Purified anti-human CD326 (EpCAM) Antibody, 100μg","description":"\u003cp\u003eCD326 is also known as Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly expressed in bone marrow, colon, lung, and most normal epithelial cells and is expressed on carcinomas of gastrointestinal origin. Recently, it has been reported that CD326 expression occurs during the early steps of erythrogenesis. CD326 functions as a homotypic calcium-independent cell adhesion molecule and is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation. CD326 antigen is an immunotherapeutic target for the treatment of human carcinomas.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: DU.4475 breast carcinoma\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/mL\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: FC - Quality tested ICC - Verified IHC - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µL volume or 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: Additional reported applications (for the revelant formats) include: immunofluorescence, immunohistochemistry3, and spatial biology (IBEX)4,5.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Lammers R, et al. 2002. Exp. Hematol. 30:537. Schultz LD, et al. 2010. P. Natl. Acad. Sci. USA 107:13022. PubMed Human Protein Atlas http:\/\/www.proteinatlas.org\/ENSG00000119888\/antibody (IHC) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Genga RMJ et al. 2019. Cell reports. 27(3):708-718 . PubMed Wang J, et al. 2023. ACS Sens. 8:1200. PubMed Yildizhan Y, et al. 2023. Int J Mol Sci. 24:. PubMed Qin XY, et al. 2023. Cell Death Dis. 14:358. PubMed Ramos SA, et al. 2022. J Allergy Clin Immunol. 149:767. PubMed Leader AM, et al. 2021. Cancer Cell. 39:1594. PubMed Li G, et al. 2023. Int J Mol Med. 51: . PubMed Peterson HM, et al. 2022. Adv Sci (Weinh). 9:e2200415. PubMed de Vargas Roditi L, et al. 2022. Cell Rep Med. 3:100604. PubMed Yildizhan Y, et al. 2021. J Extracell Vesicles. e12059:10. PubMed Valès S, et al. 2019. EBioMedicine. 49:172. PubMed Hutt M, et al. 2018. Oncotarget. 9:11322. PubMed Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed Hinohara K, et al. 2018. Cancer Cell. 34:939. PubMed Goh D, et al. 2022. Front Immunol. 13:939989. PubMed Morsing M, et al. 2020. Breast Cancer Res. 0.9875. PubMed Davies SP, et al. 2019. Cell Rep. 29:1610. PubMed Huerta–Nuñ ez LFE, et al. 2019. Sci Rep. 9:6419. PubMed Salerno–Goncalves R, et al. 2019. PLoS Negl Trop Dis. 13:e0007650. PubMed Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed Kaneko MK, et al. 2020. Oncol Rep. 44:2517. PubMed Batth IS, et al. 2020. BMC Cancer. 20(1):715. PubMed Poggi A, et al. 2022. Curr Protoc. 2:e366. PubMed Gee MH, et al. 2018. Cell. 172:549. PubMed Krishnan V, et al. 2020. Gut. 69:1738. PubMed Njock MS, et al. 2022. J Extracell Vesicles. 11:e12228. PubMed Ding L, et al. 2019. Nat Commun. 10:4182. PubMed Shi G, et al. 2022. Methods Mol Biol. 2394:591. PubMed Ruiz–Riquelme A, et al. 2018. Acta Neuropathol Commun. 6:26. PubMed Kim J, et al. 2018. J Histochem Cytochem. 66:879. PubMed\u003cbr\u003e\nRRID: AB_756075 (BioLegend Cat. No. 324201) AB_756076 (BioLegend Cat. No. 324202)\u003cbr\u003e\nStructure: Type I transmembrane protein, contains six disulfide bridges, one THYRO domain, approximate molecular weight 40 kD.\u003cbr\u003e\nDistribution: Highly expressed in bone marrow, colon, lung, and most normal epithelial cells. Also highly expressed on carcinomas of gastrointestinal origin. Expressed during early erythrogenesis.\u003cbr\u003e\nFunction: Homotypic calcium-independent cell adhesion. CD326 is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation.\u003cbr\u003e\nModification: Glycosylated.\u003cbr\u003e\nCell Type: Embryonic Stem Cells, Epithelial cells\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Stem Cells\u003cbr\u003e\nMolecular Family: Adhesion Molecules, CD Molecules\u003cbr\u003e\nAntigen References: 1. Strnad J, et al. 1989. Cancer Res. 49:314. 2. Munz M, et al. 2004. Oncogene 23:5748. 3. Rao CG, et al. 2005. Int. J. Oncol. 27:49.\u003cbr\u003e\nGene ID: 4072\u003cbr\u003e\nUniProt: View information about CD326 on UniProt.org\u003cbr\u003e\nClone: 9C4\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, TROP1\u003cbr\u003e\nIsotype: Mouse IgG2b, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862504558761,"sku":"324202","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-324202","provider":"Iright","version":"1.0","type":"link"}